Altimmune Publishes IMPACT Phase 2b 48-Week Data In The Lancet Gastroenterology & Hepatology
Benzinga Newsdesk 9 hours ago
BiotechGeneralNews
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profilePublication of results provides
Significant reductions across non-invasive measures of liver fat, inflammation and fibrosis observed at 48 weeks of pemvidutide treatment, with generally favorable tolerability profile
Publication of results provides further validation for the balanced 1:1 glucagon/GLP-1 dual receptor agonist profile of pemvidutide